Voyages to the (un)known: adaptive design of bioactive compounds

Trends in Biotechnology

Volumn 27, Issue 1, 2009, Pages 18-26

  Schneider, Gisbert ^a   Hartenfeller, Markus ^a   Reutlinger, Michael ^a   Tanrikulu, Yusuf ^a   Proschak, Ewgenij ^a   Schneider, Petra ^b  

^a GOETHE UNIVERSITY   (Germany)

^b Schneider Consulting GbR   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEXATION; EVOLUTIONARY ALGORITHMS; PARTICLE SWARM OPTIMIZATION (PSO);

ADAPTIVE DESIGNS; ADAPTIVE TECHNIQUES; AUTOMATED DESIGNS; BIOACTIVE COMPOUNDS; BIOACTIVE MOLECULES; COMPOUND LIBRARIES; CURRENT STATUSES; DRUG DESIGNS; LEAD STRUCTURES; MOLECULAR ASSEMBLIES; RAPID IDENTIFICATIONS; SCREENING COMPOUNDS;

LEAD COMPOUNDS;

CANNABINOID 1 RECEPTOR AGONIST; HISTAMINE H3 RECEPTOR AGONIST; POTASSIUM CHANNEL;

AUTOMATION; COMPUTER PROGRAM; DRUG ACTIVITY; DRUG DESIGN; DRUG RESEARCH; EVOLUTIONARY ALGORITHM; HUMAN; NONHUMAN; PRIORITY JOURNAL; QUANTITATIVE STRUCTURE ACTIVITY RELATION; REVIEW;

ALGORITHMS; COMBINATORIAL CHEMISTRY TECHNIQUES; DRUG DESIGN; PHARMACEUTICAL PREPARATIONS;

EID: 57849156863     PISSN: 01677799     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tibtech.2008.09.005     Document Type: Review

References (84)

1. Bleicher K.H., et al. Hit and lead generation: beyond high-throughput screening. Nat. Rev. Drug Discov. 2 (2003) 369-378
2. Schneider G., and Baringhaus K.-H. Molecular Design: Concepts and Applications (2008), Wiley-VCH, Weinheim
3. Schneider G., and Fechner U. Computer-based de novo design of drug-like molecules. Nat. Rev. Drug Discov. 4 (2005) 649-663
4. Jhoti H. Fragment-based drug discovery using rational design. Ernst Schering Found. Symp. Proc. 3 (2007) 169-185
5. Mauser H., and Guba W. Recent developments in de novo design and scaffold hopping. Curr. Opin. Drug Discov. Dev. 11 (2008) 365-374
6. Schneider G., and So S.-S. Adaptive Systems in Drug Design (2002), Landes Bioscience
7. Kauffman S.A. The Origins of Order: Self-Organization and Selection in Evolution (1993), Oxford University Press
8. Koza J.R. Genetic Programming (1992), MIT Press
9. Goldstein J. Emergence as a construct: history and issues. Emergence 1 (1999) 49-72
10. Wunberg T., et al. Improving the hit-to-lead process: data-driven assessment of drug-like and lead-like screening hits. Drug Discov. Today 11 (2006) 175-180
11. Oprea T.I., et al. Lead-like, drug-like or 'Pub-like': how different are they?. J. Comput. Aided Mol. Des. 21 (2007) 113-119
12. Rechenberg I. Evolutionsstrategie - Optimierung technischer Systeme nach Prinzipien der biologischen Evolution (1973), Frommann-Holzboog
13. Maggiora G.M., and Johnson M.A. Concepts and Applications of Molecular Similarity (1990), Wiley
14. Horvath D., and Jeandenans C. Neighborhood behavior of in silico structural spaces with respect to in vitro activity spaces-a novel understanding of the molecular similarity principle in the context of multiple receptor binding profiles. J. Chem. Inf. Comput. Sci. 43 (2003) 680-690
15. Schneider G., et al. Virtual screening for bioactive molecules by evolutionary de novo design. Angew. Chem. Int. Ed. Engl. 39 (2000) 4130-4133
16. Peltason L., and Bajorath J. SAR index: quantifying the nature of structure-activity relationships. J. Med. Chem. 50 (2007) 5571-5578
17. Duch W., et al. Artificial intelligence approaches for rational drug design and discovery. Curr. Pharm. Des. 13 (2007) 1497-1508
18. Schneider G., and Wrede P. The rational design of amino acid sequences by artificial neural networks and simulated molecular evolution: de novo design of an idealized leader peptidase cleavage site. Biophys. J. 66 (1994) 335-344
19. Weber L., et al. Optimization of the biological activity of combinatorial compound libraries by a genetic algorithm. Angew. Chem. Int. Ed. Engl. 34 (1995) 2280-2282
20. Illgen K., et al. Simulated molecular evolution in a full combinatorial library. Chem. Biol. 7 (2000) 433-441
21. Dorigo M., and Stützle T. Ant Colony Optimization (2004), MIT-Press
22. Hiss J.A., et al. Design of MHC I stabilizing peptides by agent-based exploration of sequence space. Protein Eng. Des. Sel. 20 (2007) 99-108
23. Kennedy J., and Eberhart R.C. Particle swarm optimization. Proceedings of the 1995 IEEE International Conference on Neural Networks: 1995 Nov 27-Dec 1; Perth, Australia (1995), IEEE 1942-1948
24. Kennedy J., et al. Swarm Intelligence (2001), Morgan Kauffmann
25. Poli R., et al. Particle swarm optimization - an overview. Swarm Intell. 1 (2007) 33-57
26. Hartenfeller M., et al. Concept of combinatorial de novo design of drug-like molecules by particle swarm optimization. Chem. Biol. Drug Des. 72 (2008) 16-26
27. Foloppe N., and Hubbard R. Towards predictive ligand design with free-energy based computational methods?. Curr. Med. Chem. 13 (2006) 3583-3608
28. Pierce A.C., et al. BREED: generating novel inhibitors through hybridization of known ligands. Application to CDK2, p38, and HIV protease. J. Med. Chem. 47 (2004) 2768-2775
29. Holland J.H. Adaptation in Natural and Artificial Systems (1975), University of Michigan Press
30. Schneider G., et al. De novo design of molecular architectures by evolutionary assembly of drug-derived building blocks. J. Comput. Aided Mol. Des. 14 (1999) 487-494
31. Fechner U., and Schneider G. Flux (1): a virtual synthesis scheme for fragment-based de novo design. J. Chem. Inf. Model. 46 (2006) 699-707
32. Fechner U., and Schneider G. Flux (2): comparison of molecular mutation and crossover operators for ligand-based de novo design. J. Chem. Inf. Model. 47 (2007) 656-667
33. Gillet V.J., et al. Combinatorial library design using a multiobjective genetic algorithm. J. Chem. Inf. Comput. Sci. 42 (2002) 375-385
34. Brown N., et al. A graph-based genetic algorithm and its application to the multiobjective evolution of median molecules. J. Chem. Inf. Comput. Sci. 44 (2004) 1079-1087
35. Schüller A., et al. The concept of template-based de novo design from drug-derived molecular fragments and its application to TAR RNA. J. Comput. Aided Mol. Des. 22 (2008) 59-68
36. Schneider P., and Schneider G. Collection of bioactive reference compounds for focused library design. QSAR Comb. Sci. 22 (2003) 713-718
37. Lewell X.Q., et al. RECAP - retrosynthetic combinatorial analysis procedure: a powerful new technique for identifying privileged molecular fragments with useful applications in combinatorial chemistry. J. Chem. Inf. Comput. Sci. 38 (1998) 511-522
38. Du Z., et al. Structure of TAR RNA complexed with a Tat-TAR interaction nanomolar inhibitor that was identified by computational screening. Chem. Biol. 9 (2002) 707-712
39. Agrafiotis D.K., and Cedeno W. Feature selection for structure-activity correlation using binary particle swarms. J. Med. Chem. 45 (2002) 1098-1107
40. Cedeno W., and Agrafiotis D.K. Using particle swarms for the development of QSAR models based on K-nearest neighbor and kernel regression. J. Comput. Aided Mol. Des. 17 (2003) 255-263
41. Meissner M., and Schneider G. Protein folding simulation by particle swarm optimization. Open Struct. Biol. J. 1 (2007) 1-6
42. Schneider G., et al. 'Scaffold-hopping' by topological pharmacophore search: a contribution to virtual screening. Angew. Chem. Int. Ed. Engl. 38 (1999) 2894-2896
43. Kohonen T. Self-organized formation of topologically correct feature maps. Biol. Cybern. 43 (1982) 59-69
44. Zupan J., and Gasteiger J. Neural Networks in Chemistry and Drug Design (1999), Wiley-VCH
45. Schneider G., and Schneider P. Navigation in chemical space: ligand-based design of focused compound libraries. In: Kubinyi H., and Müller G. (Eds). Chemogenomics in Drug Discovery (2004), Wiley-VCH 341-376
46. Krüger, B. et al. Scaffold-hopping potential of fragment-based de novo design: The chances and limits of variation. Comb. Chem. High Throughput Screen. (in press)
47. Tulinsky A., and Qiu X. Active site and exosite binding of α-thrombin. Blood Coagul. Fibrinolysis 4 (1993) 305-312
48. Zoete V., et al. Peroxisome proliferator-activated receptor structures: ligand specificity, molecular switch and interactions with regulators. Biochim. Biophys. Acta 1771 (2007) 915-925
49. Bode W., et al. Geometry of binding of the benzamidine- and arginine-based inhibitors Nα-(2-naphthyl-sulphonyl-glycyl)-dl-p-amidinophenylalanyl-piperidi ne (NAPAP) and (2R,4R)-4-methyl-1-[Nα-(3-methyl-1,2,3,4-tetrahydro-8-quinolinesul phonyl)-l-arginyl]-2-piperidine carboxylic acid (MQPA) to human α-thrombin. Eur. J. Biochem. 193 (1990) 175-182
50. Etgen G.J., and Mantlo N. PPAR ligands for metabolic disorders. Curr. Top. Med. Chem. 3 (2003) 1649-1661
51. Rinaldi-Carmona M., et al. SR141716A, a potent and selective antagonist of the brain cannabinoid receptor. FEBS Lett. 350 (1994) 240-244
52. Noeske T., et al. Predicting compound selectivity by self-organizing maps: cross-activities of metabotropic glutamate receptor antagonists. ChemMedChem 1 (2006) 1066-1068
53. Renner S., et al. Searching for drug scaffolds with 3D pharmacophores and neural network ensembles. Angew. Chem. Int. Ed. Engl. 46 (2007) 5336-5339
54. Congreve M., et al. Recent developments in fragment-based drug discovery. J. Med. Chem. 51 (2008) 3661-3680
55. Lin C.S., et al. Voltage-gated potassium channels regulate calcium-dependent pathways involved in human T lymphocyte activation. J. Exp. Med. 177 (1993) 637-645
56. Alig L., et al. Benzodioxoles: novel cannabinoid-1 receptor inverse agonists for the treatment of obesity. J. Med. Chem. 51 (2008) 2115-2127
57. Vinkers H.M., et al. SYNOPSIS: SYNthesize and OPtimize System in Silico. J. Med. Chem. 46 (2003) 2765-2773
58. Gillet V.J., et al. SPROUT: a program for structure generation. J. Comput. Aided Mol. Des. 7 (1993) 127-153
59. Gillet V.J., et al. SPROUT: recent developments in the de novo design of molecules. J. Chem. Inf. Comput. Sci. 34 (1994) 207-217
60. Hurt D.E., et al. Structure of Plasmodium falciparum dihydroorotate dehydrogenase with a bound inhibitor. Acta Crystallogr. D Biol. Crystallogr. 62 (2006) 312-323
61. Liu S., et al. Structures of human dihydroorotate dehydrogenase in complex with antiproliferative agents. Structure 8 (2000) 25-33
62. Heikkilä T., et al. The first de novo designed inhibitors of Plasmodium falciparum dihydroorotate dehydrogenase. Bioorg. Med. Chem. Lett. 16 (2006) 88-92
63. Stahl M., et al. A validation study on the practical use of automated de novo design. J. Comput. Aided Mol. Des. 16 (2002) 459-478
64. Roche O., and Sarmiento R.M.R. A new class of histamine H3 receptor antagonists derived from ligand based design. Bioorg. Med. Chem. Lett. 17 (2007) 3670-3675
65. Lloyd D.G., et al. Scaffold hopping in de novo design. Ligand generation in the absence of receptor information. J. Med. Chem. 47 (2004) 493-496
66. Agrafiotis D.K., et al. On the effects of permuted input on conformational sampling of drug-like molecules: an evaluation of stochastic proximity embedding. Chem. Biol. Drug Des. 70 (2007) 123-133
67. Jorgensen W.L., et al. Computer-aided design of non-nucleoside inhibitors of HIV-1 reverse transcriptase. Bioorg. Med. Chem. Lett. 16 (2006) 663-667
68. Chung S., et al. Orphan GPCR research. Br. J. Pharmacol. 153 (2008) S339-S346
69. Tanrikulu Y., and Schneider G. Pseudoreceptor models in drug design: bridging ligand- and receptor-based virtual screening. Nat. Rev. Drug Discov. 7 (2008) 667-677
70. Reitz M., et al. Query generation to search for inhibitors of enzymatic reactions. J. Chem. Inf. Model. 46 (2006) 2333-2341
71. Schneider G., et al. Peptide design by artificial neural networks and computer-based evolutionary search. Proc. Natl. Acad. Sci. U. S. A. 95 (1998) 12179-12184
72. Glen R.C., and Payne A.W.R. A genetic algorithm for the automated generation of molecules within constraints. J. Comput. Aided Mol. Des. 9 (1995) 181-202
73. Nachbar R.B. Molecular evolution: a hierarchical representation for chemical topology and its automated manipulation. Proceedings of the 3rd Annual Genetic Programming Conference: 1998 July 22-25; Madison, Wisconsin (1998), University of Wisconsin 246-253
74. Globus A., et al. Automatic molecular design using evolutionary algorithms. Nanotechnology 10 (1999) 290-299
75. Douguet D., et al. A genetic algorithm for the automated generation of small organic molecules: drug design using an evolutionary algorithm. J. Comput. Aided Mol. Des. 14 (2000) 449-466
76. Wang R., et al. LigBuilder: a multi-purpose program for structure-based drug design. J. Mol. Model. 6 (2000) 498-516
77. Pegg S.C.-H., et al. A genetic algorithm for structure based de novo design. J. Comput. Aided Mol. Des. 15 (2001) 911-933
78. Gillet V.J., et al. Designing focused libraries using MoSELECT. J. Mol. Graph. Model. 20 (2002) 491-498
79. Payne A.W., and Glen R.C. Molecular recognition using a binary genetic search algorithm. J. Mol. Graph. 11 (1993) 74-91
80. Cramer R.D., et al. Comparative molecuar field analysis (CoMFA). 1. Effect of shape on binding of steroids to carrier proteins. J. Am. Chem. Soc. 110 (1988) 5959-5967
81. Douguet D., et al. LEA3D: a computer-aided ligand design for structure-based drug design. J. Med. Chem. 48 (2005) 2457-2468
82. Dey F., and Caflisch A. Fragment-based de novo ligand design by multiobjective evolutionary optimization. J. Chem. Inf. Model. 48 (2008) 679-690
83. Meissner M., et al. Optimized particle swarm optimization (OPSO) and its application to artificial neural network training. BMC Bioinformatics 7 (2006) 125
84. Schmuker M., et al. SOMMER: self-organising maps for education and research. J. Mol. Model. 13 (2007) 225-228